Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer

M Labrie, JS Brugge, GB Mills… - Nature reviews Cancer, 2022 - nature.com
Normal cells explore multiple states to survive stresses encountered during development
and self-renewal as well as environmental stresses such as starvation, DNA damage, toxins …

Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade

K Pang, ZD Shi, LY Wei, Y Dong, YY Ma, W Wang… - Drug Resistance …, 2023 - Elsevier
The binding of programmed death-1 (PD-1) on the surface of T cells and PD-1 ligand 1 (PD-
L1) on tumor cells can prevent the immune-killing effect of T cells on tumor cells and …

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier

S Vafaei, AO Zekiy, RA Khanamir, BA Zaman… - Cancer Cell …, 2022 - Springer
Recently, immune checkpoint inhibitors (ICIs) therapy has become a promising therapeutic
strategy with encouraging therapeutic outcomes due to their durable anti-tumor effects …

Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm

Y Nakamura, A Kawazoe, F Lordick… - Nature reviews Clinical …, 2021 - nature.com
Advances in cancer biology and sequencing technology have enabled the selection of
targeted and more effective treatments for individual patients with various types of solid …

Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant

C Yang, BR Xia, ZC Zhang, YJ Zhang, G Lou… - Frontiers in …, 2020 - frontiersin.org
Ovarian cancer is the most lethal gynecologic malignancy. Surgery and chemotherapy are
the primary treatments for ovarian cancer; however, patients often succumb to recurrence …

The complementarity of DDR, nucleic acids and anti-tumour immunity

AVR Kornepati, CM Rogers, P Sung, TJ Curiel - Nature, 2023 - nature.com
Immune checkpoint blockade (ICB) immunotherapy is a first-line treatment for selected
cancers, yet the mechanisms of its efficacy remain incompletely understood. Furthermore …

Immunomodulation by targeted anticancer agents

G Petroni, A Buqué, L Zitvogel, G Kroemer, L Galluzzi - Cancer cell, 2021 - cell.com
At odds with conventional chemotherapeutics, targeted anticancer agents are designed to
inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite …

Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA)

J Hamanishi, N Takeshima, N Katsumata… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE This phase III, multicenter, randomized, open-label study investigated the
efficacy and safety of nivolumab versus chemotherapy (gemcitabine [GEM] or pegylated …

Combined PARP inhibition and immune checkpoint therapy in solid tumors

F Peyraud, A Italiano - Cancers, 2020 - mdpi.com
Genomic instability is a hallmark of cancer related to DNA damage response (DDR)
deficiencies, offering vulnerabilities for targeted treatment. Poly (ADP-ribose) polymerase …

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy

B Cheng, W Pan, Y Xing, Y Xiao, J Chen… - European Journal of …, 2022 - Elsevier
DDR (DNA damage response) defects in cells drive tumor formation by promoting DNA
mutations, which also provides cancer-specific vulnerabilities that can be targeted by …